The science of success

At Probi^® we believe that there is always more to learn—both about new strains and those we’ve used for years. We continually isolate and characterize promising strains to expand our probiotic library.

We also work closely with international partners and academic groups to conduct state-of-the-art preclinical and clinical trials that explore the underlying mechanisms and health effects of our existing probiotics. To confirm our findings and the health effects, we repeat our studies multiple times.

Read more about the academic groups we work with.

Probi has had a long and fruitful collaboration with the Department of Internal Medicine and Clinical Nutrition at the University of Gothenburg in Sweden, resulting in a number of studies investigating the effects of the probiotic strain LP299V^® on iron absorption and more recently also iron status. The ClinBac^TM concept Probi FerroSorb^® builds on the outcome of these studies.

Learn more here.

The Microbial Ecology Group at the Centre for Bacteria in Health and Disease at the University of Aberdeen, Scotland, UK, has been working together with Probi on the characterization of bacterial isolates with the potential to be used as next generation probiotics.

Learn more here.

Probi has collaborated with the Host-Microbe Interactomics Group at the Department of Animal Sciences at Wageningen University & Research in The Netherlands. The group combines expertise in cell biology, immunology, microbiology, and functional genomics to better understand the molecular interactions occurring between microbes and their hosts. Among other things, the group has done a lot of work on different Lactiplantibacillus plantarum strains.

Learn more here.

Together with a research group at the Department of Community Medicine and Rehabilitation at the University of Umeå in Sweden, Probi has investigated the effects of the strain LP299V^® on iron status in female athletes.

Learn more here.

Research groups at the School of Medical Sciences and the School of Science and Technology at Örebro University in Sweden, in collaboration with Probi and nine other Swedish companies, have been granted funding for research into novel, needle free vaccines. The goal is to develop different types of novel vaccines and investigate vaccination through mucous membranes. The delivery technology project will include the use of probiotic bacteria.

Learn more here and here.

At Probi, we are always open to new collaborations! Contact us if you have an idea or are looking for a research partner!